Revelation Biosciences Stock Quote REVB - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.58

Bid

1.58

Ask

1.69

Volume

19,656

1.58 Day's Range 1.6438

1.52 52 Week Range 28.20

Market Cap

2.58M

Previous Close

1.62

Open

1.63

Last Trade

1.58

Last Trade Time

Financial Volume

$ 31,663

VWAP

1.6109

Average Volume (3m)

700,436

Shares Outstanding

1,632,935

Dividend Yield

PE Ratio

-0.14

Earnings Per Share (EPS)

-0.07

Revenue

Net Profit

-120k

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to ... Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. Show more

Sector

Pharmaceutical Preparations

Industry

Blank Checks

Headquarters

Lewes, Delaware, USA

Founded

2022

Revelation Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker REVB. The last closing price for Revelation Biosciences was $1.62. Over the last year, Revelation Biosciences shares have traded in a share price range of $ 1.52 to $ 28.20.

Revelation Biosciences currently has 1,632,935 shares outstanding. The market capitalization of Revelation Biosciences is $2.65 million. Revelation Biosciences has a price to earnings ratio (PE ratio) of -0.14.

Form S-3 - Registration statement under Securities Act of 1933

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity- -Gemini was safe and well tolerated at pharmacologically active doses- -Phase 1...

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

-Top-line data forthcoming- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained...

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention...

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

– Prophylactic administration of Gemini (Intravenous PHAD®) reduces tissue damage and improves kidney function in a rat model of bilateral ischemic reperfusion induced acute kidney injury (AKI...

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

-Top-line data including safety, tolerability, and biomarker activity anticipated this summer- -This Phase 1 clinical study data will support further development across multiple indications...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

– Oral presentation in addition to poster presentation announced January 30, 2024 – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, as part of a...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.26	-14.1304347826	1.84	1.95	1.52	105493	1.65671757	CS
4	-0.37	-18.9743589744	1.95	2.14	1.52	121934	1.78892055	CS
12	-0.8	-33.6134453782	2.38	3.8	1.52	700436	2.34523789	CS
26	-8.42	-84.2	10	25.26	1.52	517719	3.65487293	CS
52	-22.645	-93.4778121775	24.225	28.2	1.52	310777	5.79902646	CS
156	-8797.42	-99.982043414	8799	10237.5	1.52	1218834	932.40074842	CS
260	-8797.42	-99.982043414	8799	10237.5	1.52	1218834	932.40074842	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M